Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA)

TRPMA News

Taiwan: TRPMA and DTCO Jointly Announce the Development of “TRPMA Biopharma Trusted Platform”

Taiwan: TRPMA and DTCO Jointly Announce the Development of “TRPMA Biopharma Trusted Platform”

(Source: TRPMA 2016-05-10）

Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA) announced the collaboration with Digital Treasury Corporation (DTCO) to jointly develop the “TRPMA Biopharma Trusted Platform”, an application of the latest Blockchain Technology.

Read More

Welcome to TRPMA website

Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA), composed of 28 Taiwanese innovative biopharmaceutical companies, plays a pivotal role in coordinating the resources, strengthening alliances among the industry, the academic and the government in Taiwan. TRPMA members aim to create a competitive value chain of biopharmaceutical industry to boost the nation's economy and promote the Asian and global cooperation in biopharmaceutical innovation.

Industry News

R&D: Trial results show promise for chemo-free future treatment

Promising results from a global study have shown that patients with chronic lymphocytic leukaemia (CLL) may be offered a chemotherapy-free treatment in future.

Read More
ICH Guideline: Industry groups call for changes to ICH S11 guideline

Industry groups are calling for changes to a recently released International Council for Harmonisation (ICH) S11 draft guideline on nonclinical safety testing to support the development of pediatric drugs in response to the European Medicines Agency’s (EMA) public consultation on the guideline.

Read More
NDA: Australia and Canada jointly approve breast cancer drug

As part of a push toward regulatory convergence, Health Canada and Australia’s Therapeutic Goods Administration (TGA) last week jointly approved Eli Lilly’s Verzenio (abemaciclib) for the treatment of metastatic breast cancer.

Read More